GlassScriptPhysician profile
Hussam Eltoukhy
NPI 1356737324
$2,075.03
in general payments reported to CMS, 2019-2025
30 companies · $901 in 2025
The $901 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.54 · 2023: $270 · 2024: $890 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002 · Education: $59.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,002.15 |
| Education | $59.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $370.52 | 2023-2025 | Injectafer, Vanflyta, Enhertu |
| Pfizer INC. | $217.87 | 2023-2025 | |
| Celgene Corporation | $175.11 | 2023-2025 | Reblozyl |
| Adc Therapeutics America, INC. | $113.98 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.17 | 2024-2025 | |
| Taiho Oncology, INC. | $112.65 | 2023-2025 | |
| Astellas Pharma US INC | $88.38 | 2024-2025 | Vyloy, Xospata, Padcev |
| Glaxosmithkline, LLC. | $85.24 | 2023-2025 | Ojjaara, Shingrix |
| Shield Therapeutics INC | $78.84 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $70.78 | 2024-2025 | Calquence, Enhertu |
| Mirati Therapeutics, INC. | $67.05 | 2023-2024 | Krazati |
| Incyte Corporation | $66.44 | 2024-2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $64.19 | 2024-2025 | |
| Abbvie INC. | $57.34 | 2024-2025 | |
| Gilead Sciences, INC. | $47.09 | 2024-2025 | Trodelvy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $43.56 | 2024-2025 | Xt Cdx |
| Adaptive Biotechnologies Corporation | $39.15 | 2022-2025 | Clonoseq |
| Exelixis INC. | $35.50 | 2024 | Cabometyx |
| Kite Pharma, INC. | $33.64 | 2024-2025 | Yescarta |
| Array Biopharma INC | $32.76 | 2025 | Mektovi, Lorbrena, Braftovi |
| Takeda Pharmaceuticals U.S.A., INC. | $20.87 | 2024 | Fruzaqla |
| Merck Sharp & Dohme LLC | $19.50 | 2024 | Keytruda, Lynparza |
| Genmab U.S., INC. | $17.55 | 2023 | Epkinly |
| E.R. Squibb & Sons, L.L.C. | $16.66 | 2024 | Krazati |
| Alexion Pharmaceuticals, INC. | $16.27 | 2024 | Ultomiris |
| Eisai INC. | $15.20 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $14.98 | 2023 | Epkinly |
| Pharmaessentia USA Corporation | $13.86 | 2024 | Besremi |
| Pharmacosmos Therapeutics INC. | $13.67 | 2024 | Monoferric |
| Blueprint Medicines Corporation | $13.21 | 2024 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hussam Eltoukhy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.